文献速递特殊人群用药

口服司美格鲁肽的临床药代动力学:临床药理学试验数据解析

Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.
PubMed 文献 · Clin Pharmacokinet · 2021-05-10

该分析基于六项口服司美格鲁肽临床药理学试验数据,采用群体药代动力学模型刻画其吸收、分布与消除特征,并评估影响暴露的协变量;模型准确描述各试验浓度曲线,推荐给药条件下生物利用度为0.8%,稳态暴露个体内变异为33%。

要点

  • 推荐给药条件下口服司美格鲁肽生物利用度为0.8%。
  • 餐后禁食时间、饮水量和体重是影响暴露的最重要协变量。
  • 生物利用度个体内变异137%,稳态暴露个体内变异降至33%。

核心结论

  • 更新模型可总体刻画口服、皮下及静脉给予司美格鲁肽在健康受试者和2型糖尿病受试者中的药代动力学特征。

研究设计与样本

  • 基于六项口服司美格鲁肽临床试验数据扩展既往皮下和静脉给药的两室药代动力学模型,受试者为健康志愿者或肾功能或肝功能损害者。
  • 五项试验采用多剂口服司美格鲁肽5-10 mg,一项为单剂10 mg;另用一项2型糖尿病受试者试验数据重新估计模型。

主要发现

  • 模型准确描述各试验的浓度曲线。
  • 餐后禁食时间、随服大量水和体重是影响司美格鲁肽暴露的最重要协变量。
  • 推荐给药条件(给药后禁食30 min、用水≤120 mL)下生物利用度为0.8%,生物利用度随给药后禁食时间延长而升高、随饮水量增加而降低。
  • 生物利用度个体内变异为137%,每日一次给药和长半衰期使稳态暴露个体内变异为33%。
  • 健康受试者与2型糖尿病受试者的口服生物利用度无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The absorption, distribution and elimination of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist for treating type 2 diabetes, was investigated using a population pharmacokinetic model based on data from clinical pharmacology trials. METHODS: A previously developed, two-compartment pharmacokinetic model, based on subcutaneous and intravenous semaglutide, was extended to include data from six oral semaglutide trials conducted in either healthy volunteers or subjects with renal or hepatic impairment. Five trials employed multiple doses of oral semaglutide (5-10 mg) and one was a single-dose (10 mg) trial. In a separate analysis, the model was re-estimated using data from a trial in subjects with type 2 diabetes. RESULTS: The model accurately described concentration profiles across trials. Post-dose fasting time, co-ingestion of a large water volume, and body weight were the most important covariates affecting semaglutide exposure. Bioavailability was 0.8% when oral semaglutide was dosed using the recommended dosing conditions (30 min post-dose fasting time, administered with ≤ 120 mL of water), increasing with a longer post-dose fasting time and decreasing with higher water volume. Within-subject variability in bioavailability was 137%, which with once-daily dosing and a long half-life translates into 33% within-subject variability in steady-state exposure. There was no significant difference in oral bioavailability of semaglutide in healthy subjects and subjects with type 2 diabetes. CONCLUSIONS: The updated model provided a general characterisation of semaglutide pharmacokinetics following oral, subcutaneous and intravenous administration in healthy subjects and subjects with type 2 diabetes. Within-individual variation of oral bioavailability was relatively high, but reduced considerably at steady state. CLINICALTRIALS. GOV IDENTIFIERS: NCT01572753, NCT01619345, NCT02014259, NCT02016911, NCT02249871, NCT02172313, NCT02877355.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Overgaard RV, Navarria A, Ingwersen SH, et al. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clin Pharmacokinet. 2021. PMID: 33969456. doi:10.1007/s40262-021-01025-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。